Therapeutic Response

FLT3 p.D835N status confers therapeutic sensitivity to Cytarabine in combination with Daunorubicin and Midostaurin in patients with Acute Myeloid Leukemia.

Statements

Source and description

Rydapt (midostaurin) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. Midostaurin's product label notes that midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.